Letter by Vos et al Regarding Article, “Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with interest the article by Ridker et al1 that proposes, based on 2 rosuvastatin trials, JUPITER (Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) and HOPE-3 (Heart Outcomes Prevention Evaluation), that there would be a probable statin mortality benefit in primary prevention in the elderly.2,3 The article relies on the combined end point of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death, but without separating these …